Baird raised the firm’s price target on Edwards Lifesciences (EW) to $79 from $78 and keeps a Neutral rating on the shares. The firm updated its model following strong Q2 results and the beat raises confidence in the second half 2025 TAVR acceleration.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EW:
- Edwards Lifesciences price target raised to $89 from $85 at RBC Capital
- Edwards Lifesciences price target raised to $81 from $75 at Canaccord
- Edwards Lifesciences price target raised to $94 from $85 at Deutsche Bank
- Edwards Lifesciences price target raised to $85 from $80 at JPMorgan
- Edwards Lifesciences: Strong Financial Performance and Strategic Advancements Drive Buy Rating